# A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Study · id `cardio:ct-nct03848793` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03848793](<https://clinicaltrials.gov/study/NCT03848793>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03848793

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

## Technical summary

Registry record NCT03848793. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-06 (actual); primary completion 2020-06-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 128 participants (enrolled count; ClinicalTrials.gov record NCT03848793, source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)
- Started: 2019-03-06 (actual) (ClinicalTrials.gov record NCT03848793, source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)
- Primary completion: 2020-06-04 (actual) (ClinicalTrials.gov record NCT03848793, source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)
- Completion: 2020-12-14 (actual) (ClinicalTrials.gov record NCT03848793, source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03848793, source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03848793-2022-11-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): HS-20004
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: ba824af4ad6cf59f55cfe99425aa27c37f11187710bcd053512d8597d2fddba6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
